Galanthamine
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 596223

CAS#: 357-70-0 (free base)

Description: Galanthamine is a potent acetylcholinesterase (AChE) inhibitor with IC50 of 500 nM.

Chemical Structure

img
Galanthamine
CAS# 357-70-0 (free base)
Instruction

Theoretical Analysis

MedKoo Cat#: 596223
Name: Galanthamine
CAS#: 357-70-0 (free base)
Chemical Formula: C17H21NO3
Exact Mass: 287.15
Molecular Weight: 287.350
Elemental Analysis: C, 71.06; H, 7.37; N, 4.87; O, 16.70

Price and Availability

Size Price Availability Quantity
10mg USD 285 2 weeks
25mg USD 550 2 Weeks
50mg USD 850 2 Weeks
Bulk inquiry

Related CAS #: 1953-04-4 (HBr)   357-70-0 (free base)  

Synonym: Galanthamine; HSDB 7361; Reminyl; NSC 100058; NSC100058; NSC-100058; BRN 0093736;

IUPAC/Chemical Name: (4aS,6R,8aS)-3-methoxy-11-methyl-4a,5,9,10,11,12-hexahydro-6H-benzo[2,3]benzofuro[4,3-cd]azepin-6-ol

InChi Key: ASUTZQLVASHGKV-JDFRZJQESA-N

InChi Code: InChI=1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1

SMILES Code: O[C@H]1C=C[C@@]23CCN(C)CC4=CC=C(OC)C(O[C@@]3([H])C1)=C24

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 287.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Chougule M, Shoyele SA, Alexander A. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Control Release. 2018 May 14. pii: S0168-3659(18)30268-2. doi: 10.1016/j.jconrel.2018.05.011. [Epub ahead of print] Review. PubMed PMID: 29772289.

2: Hsu WY, Lane HY, Lin CH. Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer's Disease, and Parkinson's Disease. Front Psychiatry. 2018 Apr 4;9:91. doi: 10.3389/fpsyt.2018.00091. eCollection 2018. Review. PubMed PMID: 29670547; PubMed Central PMCID: PMC5893641.

3: Tammenmaa-Aho I, Asher R, Soares-Weiser K, Bergman H. Cholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018 Mar 19;3:CD000207. doi: 10.1002/14651858.CD000207.pub2. Review. PubMed PMID: 29553158.

4: Mezeiova E, Spilovska K, Nepovimova E, Gorecki L, Soukup O, Dolezal R, Malinak D, Janockova J, Jun D, Kuca K, Korabecny J. Profiling donepezil template into multipotent hybrids with antioxidant properties. J Enzyme Inhib Med Chem. 2018 Dec;33(1):583-606. doi: 10.1080/14756366.2018.1443326. Review. PubMed PMID: 29529892.

5: Kalász H, Ojha S, Tekes K, Szőke É, Mohanraj R, Fahim M, Adeghate E, Adem A. Pharmacognostical Sources of Popular Medicine To Treat Alzheimer's Disease. Open Med Chem J. 2018 Feb 16;12:23-35. doi: 10.2174/1874104501812010023. eCollection 2018. Review. PubMed PMID: 29515678; PubMed Central PMCID: PMC5827296.

6: Khoury R, Rajamanickam J, Grossberg GT. An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine. Ther Adv Drug Saf. 2018 Mar;9(3):171-178. doi: 10.1177/2042098617750555. Epub 2018 Jan 8. Review. PubMed PMID: 29492246; PubMed Central PMCID: PMC5810854.

7: Gómez-Coronado N, Walker AJ, Berk M, Dodd S. Current and Emerging Pharmacotherapies for Cessation of Tobacco Smoking. Pharmacotherapy. 2018 Feb;38(2):235-258. doi: 10.1002/phar.2073. Epub 2018 Jan 29. Review. PubMed PMID: 29250815.

8: Sahoo AK, Dandapat J, Dash UC, Kanhar S. Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease. J Ethnopharmacol. 2018 Apr 6;215:42-73. doi: 10.1016/j.jep.2017.12.015. Epub 2017 Dec 14. Review. PubMed PMID: 29248451.

9: May BH, Feng M, Hyde AJ, Hügel H, Chang SY, Dong L, Guo X, Zhang AL, Lu C, Xue CC. Comparisons between traditional medicines and pharmacotherapies for Alzheimer disease: A systematic review and meta-analysis of cognitive outcomes. Int J Geriatr Psychiatry. 2018 Mar;33(3):449-458. doi: 10.1002/gps.4830. Epub 2017 Dec 14. Review. PubMed PMID: 29239495.

10: Seo EJ, Fischer N, Efferth T. Phytochemicals as inhibitors of NF-κB for treatment of Alzheimer's disease. Pharmacol Res. 2018 Mar;129:262-273. doi: 10.1016/j.phrs.2017.11.030. Epub 2017 Nov 24. Review. PubMed PMID: 29179999.

11: Hiremathad A, Piemontese L. Heterocyclic compounds as key structures for the interaction with old and new targets in Alzheimer's disease therapy. Neural Regen Res. 2017 Aug;12(8):1256-1261. doi: 10.4103/1673-5374.213541. Review. PubMed PMID: 28966636; PubMed Central PMCID: PMC5607816.

12: Kim SH, Kandiah N, Hsu JL, Suthisisang C, Udommongkol C, Dash A. Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer's disease. Br J Pharmacol. 2017 Dec;174(23):4224-4232. doi: 10.1111/bph.14030. Epub 2017 Oct 29. Review. PubMed PMID: 28901528; PubMed Central PMCID: PMC5715569.

13: Swedish Council on Health Technology Assessment. Dementia -- Caring, Ethics, Ethnical and Economical Aspects: A Systematic Review [Internet]. Stockholm: Swedish Council on Health Technology Assessment (SBU); 2008 Jun. Available from http://www.ncbi.nlm.nih.gov/books/NBK447961/ PubMed PMID: 28876770.

14: Glynn-Servedio BE, Ranola TS. AChE Inhibitors and NMDA Receptor Antagonists in Advanced Alzheimer's Disease. Consult Pharm. 2017 Sep 1;32(9):511-518. doi: 10.4140/TCP.n.2017.511. Review. PubMed PMID: 28855009.

15: Mehta N, Rodrigues C, Lamba M, Wu W, Bronskill SE, Herrmann N, Gill SS, Chan AW, Mason R, Day S, Gurwitz JH, Rochon PA. Systematic Review of Sex-Specific Reporting of Data: Cholinesterase Inhibitor Example. J Am Geriatr Soc. 2017 Oct;65(10):2213-2219. doi: 10.1111/jgs.15020. Epub 2017 Aug 18. Review. PubMed PMID: 28832937.

16: Prinsloo G, Marokane CK, Street RA. Anti-HIV activity of southern African plants: Current developments, phytochemistry and future research. J Ethnopharmacol. 2018 Jan 10;210:133-155. doi: 10.1016/j.jep.2017.08.005. Epub 2017 Aug 12. Review. PubMed PMID: 28807850.

17: Farooq MU, Min J, Goshgarian C, Gorelick PB. Pharmacotherapy for Vascular Cognitive Impairment. CNS Drugs. 2017 Sep;31(9):759-776. doi: 10.1007/s40263-017-0459-3. Review. PubMed PMID: 28786085.

18: Euwema MS, Swanson TJ. Toxicity, Deadly Single Dose Agents. 2017 Oct 6. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK441849/ PubMed PMID: 28722879.

19: Ramsay RR, Tipton KF. Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs. Molecules. 2017 Jul 15;22(7). pii: E1192. doi: 10.3390/molecules22071192. Review. PubMed PMID: 28714881.

20: Zanforlin E, Zagotto G, Ribaudo G. An Overview of New Possible Treatments of Alzheimer's Disease, Based on Natural Products and Semi-Synthetic Compounds. Curr Med Chem. 2017 Nov 17;24(34):3749-3773. doi: 10.2174/0929867324666170712161829. Review. PubMed PMID: 28707586.